2024-08-28 18:00:04
A team of researchers from the University of Massachusetts Amherst and the University of Massachusetts Chan School of Medicine (USA) has developed a new experimental treatment that has been shown to be effective in reducing and eliminating pancreatic cancer tumors in mice. This preview, published in the magazine ‘Medicine Translational Science‘, presents a new strategy that combines the activation of immune pathways with a drug delivery system through nanoparticles.
The study focused on pancreatic ductal adenocarcinoma (PDAC), the most common and deadly form of pancreatic cancer, which has a five-year survival rate of only 13%.
One of the biggest challenges in treating PDAC is itself tumor microenvironmentwhich creates a barrier that prevents immune infiltration and the effectiveness of conventional treatments.
The researchers managed to incorporate two agonists, STING and TRL4, in lipid nanoparticles, which allowed these substances to enter the tumor microenvironment and activate a strong immune response. In combination with targeted therapy (T / P), this method resulted in eight out of nine treated mice experiencing significant tumor shrinkage, and in two of them, the tumors were completely removed.
Although the tumors returned after stopping treatment, researchers consider this an important step toward developing more effective treatments for pancreatic cancer and other types of cancers.
This progress can open the door to more personalized and effective treatments for patients with difficult-to-treat cancers.
#experimental #treatment #removed #pancreatic #cancer #mice